Daily Stock Analysis, ACIU, AC Immune Ltd, priceseries

AC Immune Ltd. Daily Stock Analysis
Stock Information
Open
3.93
Close
3.90
High
3.95
Low
3.89
Previous Close
3.91
Daily Price Gain
-0.01
YTD High
12.14
YTD High Date
Jan 16, 2019
YTD Low
3.25
YTD Low Date
Jan 30, 2019
YTD Price Change
-6.32
YTD Gain
-61.84%
52 Week High
17.40
52 Week High Date
Jul 23, 2018
52 Week Low
3.25
52 Week Low Date
Jan 30, 2019
52 Week Price Change
-7.50
52 Week Gain
-65.79%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Aug 30. 2017
7.63
Sep 21. 2017
10.29
15 Trading Days
34.92%
Link
LONG
Oct 11. 2018
8.01
Oct 23. 2018
8.73
8 Trading Days
9.00%
Link
LONG
Nov 15. 2018
9.65
Dec 6. 2018
10.52
13 Trading Days
8.99%
Link
Company Information
Stock Symbol
ACIU
Exchange
NasdaqGM
Company URL
http://www.acimmune.com
Company Phone
41 21 345 91 21
CEO
Andrea Pfeifer
Headquarters
-
Business Address
EPFL INNOVATION PARK, BUILDING B, 1015 LAUSANNE, SWITZERLAND 00000
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001651625
About

AC Immune SA is a clinical stage biopharmaceutical company, which engages in leveraging two proprietary technology platforms to discover, design and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. It's products include: crenezumab, humanized, monoclonal, conformation-specific anti-Abeta antibody that developed using the SupraAntigen™ platform. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, and Andrea Pfeifer on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Description

AC Immune SA is a biopharmaceutical company. It is engaged in leveraging its two proprietary technology platforms to discover, design and develop novel, proprietary medicines for treatment of neurodegenerative diseases.